Infectious Dis. Medical News about Ganciclovir

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system
Journal of Clinical Virology, 09/24/09

Oliver SE et al. – Infants with symptomatic congenital CMV involving the CNS receiving intravenous ganciclovir therapy have fewer developmental delays at 6 and 12 months compared with untreated infants. Based on these data as well as the previously published data regarding ganciclovir treatment and hearing outcomes, 6 weeks of intravenous ganciclovir therapy can be considered in the management of babies with symptomatic congenital CMV disease involving the CNS. If treatment is initiated, it should be started within the first month of life and patients should be monitored closely for toxicity, especially neutropenia.

<< Previous
Pitfalls of diagnostic laparoscopy in abdominal tuberculosis

Next >>
Infections in Patients with Multiple Myeloma in the Era of...

Intravitreal loading injection of ganciclovir with or without adjunctive oral valganciclovir for cytomegalovirus anterior uveitis
Graefe's Archive for Clinical and Experimental Ophthalmology, 10/02/09 Relevance Score: 84%

Testing the susceptibility of human herpesviruses to antivirals
Future Microbiology, 11/18/09 Relevance Score: 80%

Treatment Strategies to Minimize or Prevent Chronic Allograft Dysfunction in Pediatric Renal Transplant Recipients
Pediatric Drugs, 11/05/09 Relevance Score: 80%

Comparison of higher dose and lower dose ganciclovir for cytomegalovirus prophylaxis in seropositive heart transplant recipients
Transplant Infectious Disease, 10/16/09 Relevance Score: 80%

The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures
Medicinal Research Reviews, 10/21/09 Relevance Score: 77%